Author:
García-Carrillo Rosendo,Molina-Pelayo Francisco A.,Zarate-Lopez David,Cabrera-Aguilar Alejandro,Ortega-Domínguez Bibiana,Domínguez-López Mariana,Chiquete-Félix Natalia,Dagnino-Acosta Adan,Velasco-Loyden Gabriela,Chávez Enrique,Castro-Sánchez Luis,de Sánchez Victoria Chagoya
Abstract
AbstractHepatocellular carcinoma (HCC) progression is associated with dysfunctional mitochondria and bioenergetics impairment. However, no data about the relationship between mitochondrial supercomplexes (hmwSC) formation and ATP production rates in HCC are available. Our group has developed an adenosine derivative, IFC-305, which improves mitochondrial function, and it has been proposed as a therapeutic candidate for HCC. We aimed to determine the role of IFC-305 on both mitochondrial structure and bioenergetics in a sequential cirrhosis-HCC model in rats. Our results showed that IFC-305 administration decreased the number and size of liver tumors, reduced the expression of tumoral markers, and reestablished the typical architecture of the hepatic parenchyma. The livers of treated rats showed a reduction of mitochondria number, recovery of the mtDNA/nDNA ratio, and mitochondrial length. Also, IFC-305 increased cardiolipin and phosphatidylcholine levels and promoted hmwSC reorganization with changes in the expression levels of hmwSC assembly-related genes. IFC-305 in HCC modified the expression of several genes encoding elements of electron transport chain complexes and increased the ATP levels by recovering the complex I, III, and V activity. We propose that IFC-305 restores the mitochondrial bioenergetics in HCC by normalizing the quantity, morphology, and function of mitochondria, possibly as part of its hepatic restorative effect.
Funder
Consejo Nacional de Humanidades, Ciencias y Tecnologías
Universidad Nacional Autónoma de México
Publisher
Springer Science and Business Media LLC